News | February 24, 2026
biomodal expands multiomic reach with Element Biosciences pact
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
The order will cover the manufacturing of bulk vaccine in 2026
Net sales reached CHF 1,327.8 million, up 2.6% year-on-year in Swiss francs, or 4.3% at constant exchange rates
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
Subscribe To Our Newsletter & Stay Updated
